A detailed history of Virtus ETF Advisers LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 7,638 shares of RARE stock, worth $360,819. This represents 0.21% of its overall portfolio holdings.

Number of Shares
7,638
Previous 7,638 -0.0%
Holding current value
$360,819
Previous $313,000 35.46%
% of portfolio
0.21%
Previous 0.16%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$37.42 - $51.61 $24,734 - $34,114
-661 Reduced 7.96%
7,638 $313,000
Q1 2024

May 15, 2024

BUY
$43.02 - $53.69 $51,365 - $64,105
1,194 Added 16.81%
8,299 $387,000
Q4 2023

Feb 15, 2024

BUY
$31.73 - $49.19 $32,777 - $50,813
1,033 Added 17.01%
7,105 $339,000
Q3 2023

Nov 07, 2023

SELL
$34.92 - $46.66 $27,516 - $36,768
-788 Reduced 11.49%
6,072 $216,000
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $3,100 - $4,328
83 Added 1.22%
6,860 $316,000
Q1 2023

May 15, 2023

BUY
$36.99 - $48.71 $4,512 - $5,942
122 Added 1.83%
6,777 $271,000
Q4 2022

Feb 14, 2023

BUY
$33.72 - $46.33 $56,986 - $78,297
1,690 Added 34.04%
6,655 $308,000
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $2,797 - $4,629
70 Added 1.43%
4,965 $206,000
Q2 2022

Aug 12, 2022

BUY
$45.8 - $85.4 $15,800 - $29,463
345 Added 7.58%
4,895 $292,000
Q4 2021

Feb 14, 2022

BUY
$73.71 - $87.86 $7,370 - $8,786
100 Added 2.25%
4,550 $383,000
Q3 2021

Nov 15, 2021

SELL
$77.92 - $102.4 $31,401 - $41,267
-403 Reduced 8.3%
4,450 $401,000
Q2 2021

Aug 10, 2021

BUY
$92.19 - $115.71 $70,617 - $88,633
766 Added 18.74%
4,853 $463,000
Q1 2021

May 17, 2021

BUY
$106.9 - $167.73 $12,293 - $19,288
115 Added 2.9%
4,087 $465,000
Q4 2020

Feb 12, 2021

SELL
$84.4 - $177.39 $389,506 - $818,654
-4,615 Reduced 53.74%
3,972 $550,000
Q3 2020

Nov 13, 2020

BUY
$72.98 - $90.0 $52,764 - $65,070
723 Added 9.19%
8,587 $706,000
Q2 2020

Aug 05, 2020

SELL
$46.91 - $78.22 $277,238 - $462,280
-5,910 Reduced 42.91%
7,864 $615,000
Q1 2020

May 14, 2020

SELL
$33.8 - $62.9 $39,275 - $73,089
-1,162 Reduced 7.78%
13,774 $612,000
Q4 2019

Feb 13, 2020

BUY
$36.08 - $45.83 $101,673 - $129,148
2,818 Added 23.25%
14,936 $638,000
Q3 2019

Nov 12, 2019

SELL
$42.5 - $63.11 $86,870 - $128,996
-2,044 Reduced 14.43%
12,118 $518,000
Q2 2019

Aug 13, 2019

SELL
$54.93 - $74.36 $122,109 - $165,302
-2,223 Reduced 13.57%
14,162 $899,000
Q1 2019

May 14, 2019

BUY
$39.87 - $69.36 $128,979 - $224,379
3,235 Added 24.6%
16,385 $1.14 Million
Q4 2018

Feb 05, 2019

BUY
$38.89 - $77.3 $144,243 - $286,705
3,709 Added 39.29%
13,150 $572,000
Q3 2018

Nov 14, 2018

BUY
$71.81 - $90.15 $46,461 - $58,327
647 Added 7.36%
9,441 $721,000
Q2 2018

Aug 10, 2018

SELL
$48.54 - $85.31 $397,494 - $698,603
-8,189 Reduced 48.22%
8,794 $676,000
Q1 2018

May 14, 2018

BUY
$44.33 - $58.52 $402,959 - $531,946
9,090 Added 115.17%
16,983 $866,000
Q4 2017

Feb 14, 2018

BUY
$43.54 - $57.32 $111,027 - $146,166
2,550 Added 47.73%
7,893 $366,000
Q3 2017

Nov 14, 2017

BUY
$49.79 - $66.32 $24,297 - $32,364
488 Added 10.05%
5,343 $285,000
Q2 2017

Aug 14, 2017

BUY
N/A
4,855
4,855 $302,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.31B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.